Delisted from NASDAQ in Aug 2023
ONCS - OncoSec Medical Incorporated
NASDAQ
->
Healthcare
->
Biotechnology
Pennington,
United States
Type: Equity
ONCS price evolution
ONCS
| (in millions $) | 3 Mar 2023 | 31 Jan 2023 | 31 Aug 2022 | 30 May 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $3.68 | $5.73 | $12.3 | |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $6.44 | $8.63 | $15.23 | $21.14 |
| Long term investments | ||||
| Property, plant & equipment | $1.52 | $4.86 | $5.64 | $5.93 |
| Goodwill & intangible assets | $0.34 | $0.36 | $0.38 | |
| Total noncurrent assets | $2.43 | $5.81 | $6.65 | |
| Total investments | ||||
| Total assets | $8.87 | $14.44 | $21.88 | $27.99 |
| Current liabilities | ||||
| Accounts payable | $4.69 | $4.8 | $4.21 | |
| Deferred revenue | ||||
| Short long term debt | $1.34 | $1.64 | $2.05 | |
| Total current liabilities | $7.23 | $6.91 | $6.63 | $4.69 |
| Long term debt | $1.91 | $2.13 | $3.51 | $4.13 |
| Total noncurrent liabilities | $7.13 | $8.51 | $9.13 | |
| Total debt | $3.46 | $5.15 | $6.17 | |
| Total liabilities | $14.36 | $15.42 | $15.76 | $14.11 |
| Shareholders' equity | ||||
| Retained earnings | -$300.88 | -$290.65 | -$282.37 | -$274.15 |
| Other shareholder equity | $0.15 | $0.9 | $0.25 | $0.18 |
| Total shareholder equity | -$5.49 | -$0.98 | $6.12 | |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $12.3 | $45.95 | $20.35 | $25.15 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $15.23 | $49.18 | $22.82 | $28.51 |
| Long term investments | ||||
| Property, plant & equipment | $5.64 | $6.37 | $6.76 | $1.03 |
| Goodwill & intangible assets | $0.38 | $0.45 | ||
| Total noncurrent assets | $6.65 | $7.1 | $7.08 | $1.38 |
| Total investments | ||||
| Total assets | $21.88 | $56.28 | $29.9 | $29.89 |
| Current liabilities | ||||
| Accounts payable | $4.21 | $5.56 | $7.92 | $4.22 |
| Deferred revenue | ||||
| Short long term debt | $2.05 | $2.08 | $1.47 | $0.08 |
| Total current liabilities | $6.63 | $7.96 | $9.68 | $4.98 |
| Long term debt | $4.13 | $5.24 | $6.35 | |
| Total noncurrent liabilities | $9.13 | $10.24 | $6.35 | $0.64 |
| Total debt | $6.17 | $7.32 | $7.82 | $0.08 |
| Total liabilities | $15.76 | $18.2 | $16.03 | $5.61 |
| Shareholders' equity | ||||
| Retained earnings | -$285.96 | -$251.78 | -$206.61 | -$164.36 |
| Other shareholder equity | $0.25 | -$0.08 | -$0.02 | $0.17 |
| Total shareholder equity | $6.12 | $38.08 | $13.87 | $24.28 |
| (in millions $) | 3 Mar 2023 | 31 Jan 2023 | 31 Aug 2022 | 30 May 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $7.66 | $8.13 | $9.55 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0 | $0 | -$3.34 | |
| Interest expense | $0.82 | -$0.12 | -$0.04 | |
| Net income | ||||
| Net income | -$6.86 | -$8.22 | -$6.25 | |
| Income (for common shares) | ||||
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $25.82 | $34.1 | $25.1 | $18.45 |
| Selling, general & administrative | $11.19 | $14.28 | $18.31 | $11.97 |
| Total operating expenses | $37.01 | $48.38 | $43.22 | $29.98 |
| Operating income | -$37.01 | -$48.38 | -$43.22 | -$29.98 |
| Income from continuing operations | ||||
| EBIT | -$37.49 | -$47.56 | -$43.12 | -$30.27 |
| Income tax expense | -$3.33 | -$2.41 | -$0.87 | $0 |
| Interest expense | $0.02 | $0.02 | $0.01 | $0 |
| Net income | ||||
| Net income | -$34.18 | -$45.17 | -$42.25 | -$30.28 |
| Income (for common shares) | -$34.18 | -$45.17 | -$42.25 | -$30.28 |
| (in millions $) | 3 Mar 2023 | 31 Dec 2022 | 31 Aug 2022 | 30 May 2022 |
|---|---|---|---|---|
| Net income | -$6.86 | |||
| Operating activities | ||||
| Depreciation | $0.01 | |||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.28 | |||
| Total cash flows from operations | -$6.61 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.01 | -$0.24 | -$0.24 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3.5 | |||
| Net borrowings | $1.61 | |||
| Total cash flows from financing | $4.16 | $4.5 | -$1.16 | -$0.92 |
| Effect of exchange rate | -$0.02 | $0.08 | -$0.11 | -$0.09 |
| Change in cash and equivalents | -$8.62 | -$2.05 | -$33.65 | -$26.47 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$34.18 | -$45.17 | -$42.25 | -$30.28 |
| Operating activities | ||||
| Depreciation | $1.07 | $1.08 | $0.99 | $0.24 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.69 | $5.6 | $4.45 | $4.35 |
| Total cash flows from operations | -$32.14 | -$41.79 | -$33.15 | -$29 |
| Investing activities | ||||
| Capital expenditures | -$0.24 | -$0.3 | -$0.01 | |
| Investments | $23.21 | |||
| Total cash flows from investing | -$0.24 | -$0.8 | $23.2 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.2 | $68.28 | $29.98 | $28.49 |
| Net borrowings | -$1.33 | -$0.62 | $0.81 | -$0.08 |
| Total cash flows from financing | -$1.16 | $68.21 | $28.4 | $27.2 |
| Effect of exchange rate | -$0.11 | -$0.02 | -$0.05 | -$0.05 |
| Change in cash and equivalents | -$33.65 | $25.6 | -$4.79 | $21.34 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 2.97M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 2.58 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.89 |
| Quick ratio | N/A |